GHRP-6

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that mimics the hormone ghrelin, binding to the ghrelin receptor (GHSR1a) to stimulate the release of growth hormone (GH) from the pituitary gland Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. It was one of the earliest growth hormone secretagogues developed, preceding the identification of ghrelin itself Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Research has primarily concentrated on its GH-releasing properties in animal models; human GH stimulation data are not present in the current research corpus. However, a growing body of preclinical work has uncovered additional actions: it can increase appetite, protect cardiac tissue after experimental heart attacks, speed recovery from acute kidney injury, and reduce lung scarring in animal models Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation+3. These diverse effects likely arise because the ghrelin receptor is found in many tissues beyond the hypothalamus and pituitary, including the heart, kidneys, and immune cells Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Because GHRP-6 strongly stimulates hunger, it is less selective than newer agents like ipamorelin, which can boost GH without as much appetite drive Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It is not FDA-approved and remains an investigational compound for research purposes only Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

GHRP-6 works by binding to and activating the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a (GHSR1a). This receptor is a G-protein-coupled receptor that naturally responds to the hormone ghrelin, which is often called the 'hunger hormone' because it rises before meals and drops after eating Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin+1.

Once activated by GHRP-6, the receptor triggers a signaling cascade inside cells. The most prominent pathway involves Gαq/11 proteins, which lead to increased intracellular calcium and the activation of protein kinases, ultimately causing the pituitary gland to release stored growth hormone into the bloodstream Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Additionally, the same receptor can couple to other G-proteins and β-arrestin, turning on survival signals like PI3K/AKT and ERK, which may explain why GHRP-6 can protect cells in the heart, kidneys, and lungs beyond just raising GH Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

The appetite-stimulating effect comes from direct activation of ghrelin receptors on specific neurons in the brain's arcuate nucleus. In mice, delivering GHRP-6 via the nose (intranasal) activated these neurons and caused a significant increase in food intake by boosting both meal size and frequency, while also raising blood GH Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice. This demonstrates that GHRP-6 can directly engage brain ghrelin pathways, not just act through the pituitary.

Unlike simply injecting growth hormone, GHRP-6 prompts the body's own pulsatile GH release, which more closely mimics natural physiology. However, because the ghrelin receptor influences many systems, GHRP-6's effects are broader and less targeted than some newer secretagogues Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

GH Stimulation (Preclinical)

While GHRP-6 has been historically investigated as a growth hormone secretagogue in human studies, the specific intravenous (1 μg/kg) and oral (300 μg/kg) GH stimulation protocols are not supported by the current research corpus, and no human GH stimulation study with GHRP-6 is included in the provided evidence. The most well-documented human effect in the available literature is limited to preclinical models.

Appetite Increase (Animal and Community)

As a ghrelin mimetic, GHRP-6 robustly stimulates hunger. In mice, intranasal GHRP-6 increased both meal frequency and size, activating specific brain circuits that promote feeding Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice. Community reports consistently note a strong hunger surge, making GHRP-6 popular in contexts where appetite stimulation is desired but problematic during calorie restriction Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Cardiac Protection (Animal)

In a rat model of heart attack, daily administration of 0.4 mg/kg GHRP-6 for one week reduced harmful ventricular remodeling, improved pumping efficiency, and showed a trend toward lower mortality Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. These effects were associated with shifts in heart muscle proteins toward more efficient energy metabolism and reduced cell death.

Kidney Protection (Animal)

A specially formulated GHRP-6 hydrogel delivered into the kidney after an ischemic injury improved filtration function, reduced cellular damage, and activated repair signaling through the mTOR pathway Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. This suggests potential for acute kidney injury, though human data are absent.

Lung and Multi-Organ Protection (Animal)

GHRP-6 reduced inflammation and collagen buildup in mouse models of acute lung injury, pointing to anti-fibrotic potential Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis. Earlier studies also noted broad protective effects across the liver, intestines, lungs, and kidneys after systemic inflammatory injury Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.

Neuroprotection (Preclinical Combo)

When combined with epidermal growth factor, GHRP-6 showed some benefit in preclinical stroke models and a small human trial, but it is unclear how much GHRP-6 contributed independently A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke+1.

Evidence for other uses such as body composition improvement or anti-aging is mostly anecdotal and not supported by robust human trials Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Formal research dosing protocols for GHRP-6 vary widely depending on the route and goal. The human GH stimulation data previously cited (intravenous 1 μg/kg and oral 300 μg/kg) are not represented in the current research corpus, and no human GH stimulation study with GHRP-6 is verified here. Therefore, the best available evidence remains preclinical.

Preclinical therapeutic studies use different regimens:

• Cardiac repair in rats: 0.4 mg/kg injected into the abdomen once daily for 7 days after a heart attack significantly improved heart function Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
• Intranasal brain activation in mice: 5 mg/kg intranasal delivery markedly increased food intake and brain ghrelin signaling Intranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice.

In community research, subcutaneous protocols commonly employ doses of 100–300 mcg, injected one to three times daily, often around fasting periods, workouts, or bedtime to align with natural GH secretory patterns. Cycles typically last 6–12 weeks, sometimes with weekend breaks to maintain responsiveness [community protocol]. When appetite stimulation is desired, doses are timed shortly before meals.

Because GHRP-6 is short-acting and pulsatile, frequent daily dosing is necessary to sustain GH elevation. It is often paired with a GHRH analog like CJC-1295, which stimulates a complementary receptor on the pituitary, to enhance the overall GH response Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

GHRP-6 is supplied as a lyophilized powder that must be dissolved before use. Bacteriostatic water is the standard diluent for multi-dose vials, as it helps prevent bacterial growth during the reconstituted period [community protocol]. Sterile water can be used if the solution will be used promptly.

Reconstitution should be done gently: add the diluent slowly against the vial wall and swirl lightly to dissolve. Avoid shaking, as foaming and mechanical stress can damage the peptide Mass spectrometric and kinetics characterization of modified species of Growth Hormone Releasing Hexapeptide generated under thermal stress in different pH and buffers. Proper handling is important because GHRP-6 can degrade in solution over time, especially when exposed to heat or pH extremes Mass spectrometric and kinetics characterization of modified species of Growth Hormone Releasing Hexapeptide generated under thermal stress in different pH and buffers+1.

After reconstitution, store the solution in a refrigerator (2–8°C) and protect it from light. Typical shelf life is 14–28 days when using bacteriostatic water, or 7–14 days with sterile water [community protocol]. The dry powder can be stored refrigerated or frozen for months to years. Any solution that becomes cloudy, discolored, or contains particles should be discarded.

An interactive reconstitution calculator on this page can help determine the appropriate volumes for a given vial size and desired dose.

GHRP-6's interactions are rooted in its action on the ghrelin receptor. Co-administering other ghrelin receptor agonists (such as MK-677, ibutamoren, or GHRP-2) will amplify GH release and appetite, increasing the risk of fluid retention, insulin resistance, and side effects like lethargy Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Conversely, ghrelin receptor antagonists like [D-Lys3]-GHRP-6 will blunt GHRP-6's effects Inhibition of ghrelin activity by the receptor antagonist [D-Lys3]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model.

When used with GHRH analogs like CJC-1295, sermorelin, or tesamorelin, there is a synergistic boost in GH because the two compounds stimulate different pituitary receptors. This is a common research stack but raises the likelihood of edema, carpal tunnel-like symptoms, and glucose fluctuations Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

GHRP-6 opposes the satiety effects of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide). While not dangerous, the combination may frustrate appetite control and caloric restriction goals Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Dopamine agonists and drugs affecting prolactin may have subtle interactions because some GHRPs can mildly influence prolactin and cortisol Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

No significant interactions are documented with regenerative peptides like BPC-157 or TB-500, which are often co-administered in injury repair research without known receptor conflicts [community protocol].

There is no strong evidence from human trials that GHRP-6 induces receptor desensitization or tolerance over time. However, the ghrelin receptor is known to exhibit high constitutive activity and complex regulation, so some researchers speculate that continuous stimulation could lead to diminished responsiveness Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

In community research protocols, cycles typically last 8–12 weeks, followed by a 2–4 week break. Shorter cycles of 6–8 weeks are also common for first-time use [community protocol]. Weekend breaks (e.g., 5 days on, 2 days off) are sometimes added to maintain sensitivity.

Signals that a break may be warranted include: a fading hunger response, plateaued recovery benefits, persistent fluid retention, rising fasting glucose, or simply an accumulation of mild side effects like hand numbness or lethargy. Because GHRP-6 acts as a pulse-trigger rather than a depot, most effects fade shortly after discontinuation, and no withdrawal syndrome is described in the literature.

Cycling is not a hard requirement but is considered a practical measure to manage the compound's appetite effects and potential metabolic strain over prolonged periods.

GHRP-6 is most commonly stacked with GHRH analogs like CJC-1295 (with or without DAC) or sermorelin. This dual-pathway approach targets both the ghrelin receptor and the GHRH receptor on pituitary cells, theoretically maximizing GH output Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. The trade-off is a higher incidence of fluid retention, joint stiffness, and glucose changes.

For injury repair, GHRP-6 is often combined with BPC-157 and TB-500, based on the idea that the GH/IGF-1 boost from GHRP-6 supports tissue growth while the other peptides directly modulate healing processes. No direct receptor-level interactions are known, but additive effects on water balance are possible [community protocol].

Stacking GHRP-6 with another ghrelin agonist like MK-677 is generally avoided because it offers little additional benefit while amplifying side effects such as hunger, lethargy, and insulin resistance Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Similarly, combining with ipamorelin is not typical, since ipamorelin is more selective and stacking both does not meaningfully improve the GH response over ipamorelin alone at appropriate doses.

Research protocols that include a GLP-1 agonist like semaglutide for weight management may find GHRP-6 counterproductive because of its strong orexigenic drive, unless appetite stimulation is specifically needed to counteract GLP-1-induced anorexia.

GHRP-6 is not approved by the FDA for any medical indication and remains an investigational compound. It is categorized among growth hormone secretagogues that are primarily used in laboratory and preclinical research. No country is documented in this corpus as having licensed GHRP-6 as a prescription drug Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

In sports, GHRP-6 is explicitly prohibited at all times by the World Anti-Doping Agency (WADA) and similar anti-doping bodies. As a growth hormone-releasing peptide, it falls under the category of peptide hormones and growth factors that are banned both in and out of competition. Anti-doping laboratories actively test for GHRP-6 and its metabolites in urine Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP‐1, GHRP‐2, GHRP‐6, Hexarelin, and Ipamorelin+1.

Because it lacks regulatory approval, personal importation or possession for human use may violate laws in many countries. GHRP-6 is often sold through gray-market channels as a 'research chemical,' but such sourcing carries legal and quality risks. Athletes should be aware that even trace amounts detected in doping control can result in sanctions.

The safety profile of GHRP-6 in humans is not fully established, as no long-term clinical trials exist. Current understanding comes from animal studies, short-term human diagnostic use, and community reports.

The most consistently reported effect is a pronounced increase in appetite, which can be beneficial or unwanted depending on the research goal Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Other common effects include fluid retention (giving a 'puffy' appearance), transient elevations in blood glucose, and mild injection site reactions Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

In a 28-day dog study, intravenous doses up to 2000 μg/kg/day produced only minor, reversible signs such as hypersalivation, pale gums, reduced heart rate, and hypoactivity, with no organ toxicity. These effects were more pronounced at higher doses Subchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days. In rats, a high dose of 0.8 mg/kg caused bradycardia and was avoided in therapeutic studies, while 0.4 mg/kg was hemodynamically safe Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

Theoretical risks include worsening insulin resistance with prolonged use, as chronic GH elevation can impair glucose metabolism. There is also concern that GH/IGF-1 pathway activation could accelerate the growth of existing tumors, although no direct cancer link with GHRP-6 has been reported Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Hormonal spillover to prolactin and cortisol is possible, especially at higher doses or when combined with other secretagogues.

Pregnancy, breastfeeding, and active malignancy are absolute contraindications. Regular monitoring of IGF-1, fasting glucose, and insulin is recommended for research protocols lasting more than a few weeks Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.